4 completed, 4 terminated, 1 active not recruiting, 1 recruiting. 11 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 4, Terminated 4, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 1 | 3 | Terminated 2, Recruiting 1 |
Follow Xencor, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis XmAb942, Placebo - Ulcerative Colitis (UC) | Phase 1 / Phase 2 | Recruiting | Xencor, Inc. | 270 | 2024-10-10 | 2026-10-30 |
| Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC Vudalimab + Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed - Nonsquamous Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Xencor, Inc. | 28 | 2023-12-27 | 2026-03-13 |
| Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) Regorafenib, XmAb20717 - Colorectal Cancer, Colon Cancer | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2023-05-17 | 2024-04-29 | |
| A Study of XmAb23104 in People With Sarcoma XmAb23104 - Sarcoma | Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 6 | 2023-04-06 | 2026-04-13 |
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies vudalimab - Ovarian Cancer, Clear Cell Carcinoma | Phase 2 | Active not recruiting | Xencor, Inc. | 170 | 2022-07-21 | 2025-02-07 |
| Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) Plamotamab, Tafasitamab, Lenalidomide - Diffuse Large-cell B-cell Lymphoma | Phase 2 | Terminated | Xencor, Inc. | 3 | 2022-04-15 | 2024-04-30 |
| XmAb20717 in Advanced Biliary Tract Cancers XmAb20717 - Biliary Tract Cancer | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 27 | 2022-04-11 | 2026-09-21 |
| XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy - Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Completed | Xencor, Inc. | 72 | 2021-10-22 | 2026-05-05 |
| Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer XmAb18087, XmAb18087 ± Pembrolizumab - Merkel Cell Carcinoma, Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Xencor, Inc. | 4 | 2021-05-10 | 2023-04-20 |
| Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD) XmAb5871 - IgG4-RD | Phase 2 | Completed | Xencor, Inc. | 20 | 2016-03-01 | 2018-12-07 |
| A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus XmAb5871, Placebo to match XmAb5871 - Systemic Lupus Erythematosus | Phase 2 | Completed | Xencor, Inc. | 105 | 2016-02-16 | 2019-08-20 |
Prostatic Neoplasms (2) · Adenocarcinoma, Clear Cell (1) · Biliary Tract Neoplasms (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Colitis, Ulcerative (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Immunoglobulin G4-Related Disease (1) · Inflammatory Bowel Diseases (1) · Lupus Erythematosus, Systemic (1) · Lymphoma, Large B-Cell, Diffuse (1) · Ovarian Neoplasms (1)
Carboplatin (2) · Docetaxel (1) · Lenalidomide (1) · Pemetrexed (1) · cabazitaxel (1) · olaparib (1) · pembrolizumab (1) · regorafenib (1) · tafasitamab (1)
United States (10) · Spain (3) · Greece (2) · Portugal (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Chile (1) · Croatia (1) · France (1) · Georgia (1) · Hungary (1)
Jolene Shorr (3) · Benjamin Thompson, MD, PhD (1) · Ciara Kelly, MBBCh BAO (1) · John Stone, M.D., M.P.H. (1) · Kanwal Raghav, MD (1) · Mark O'Hara, MD (1) · Michael Chiarella (1)